In the treatment of solid cancer, moreover, the spectacular efficacy of the CAR T cell treatment could not be reproduced, raising the hypothesis whether the CD19+ healthy B cells can act as stimulators to boost the anti-leukemia/lymphoma activity of the CD19 CAR T cells. This evidence concerns the gene CD19 and lymphoma.